Jump to main content
Jump to site search

Issue 67, 2020
Previous Article Next Article

First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases

Author affiliations

Abstract

We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development.

Graphical abstract: First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases

Back to tab navigation

Supplementary files

Article information


Submitted
18 Jun 2020
Accepted
26 Jun 2020
First published
09 Jul 2020

Chem. Commun., 2020,56, 9695-9698
Article type
Communication

First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases

M. T. Gabr and F. Barbault, Chem. Commun., 2020, 56, 9695
DOI: 10.1039/D0CC04249H

Social activity

Search articles by author

Spotlight

Advertisements